FIELD: organic chemistry.
SUBSTANCE: group of inventions includes compounds 94, 99, 101, a pharmaceutical composition based thereon and use thereof.
EFFECT: compounds 94, 99, 101, having RET-kinase inhibitor activity.
9 cl, 10 tbl, 39 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DESTRUCTION OF ANDROGEN RECEPTORS AND USE THEREOF | 2020 |
|
RU2825000C2 |
| CELL NECROSIS INHIBITOR, METHOD FOR ITS PRODUCTION AND APPLICATION | 2019 |
|
RU2793918C2 |
| USE OF DIARYLTHIOHYDANTOIN COMPOUND AS AN ANDROGEN RECEPTOR ANTAGONIST | 2018 |
|
RU2804108C9 |
| FAK INHIBITOR AND DRUG COMBINATIONS THEREWITH | 2019 |
|
RU2820555C2 |
| NOVEL AGONIST OF β-RECEPTOR OF THYROID HORMONES | 2021 |
|
RU2839610C1 |
| NOVEL AURORA KINASE INHIBITOR AND USE THEREOF | 2020 |
|
RU2835080C1 |
| CETP INHIBITORS | 2006 |
|
RU2513107C2 |
| SUBSTITUTED 2H-PYRAZOLE DERIVATIVE | 2016 |
|
RU2722363C2 |
| MAS-COUPLED G-PROTEIN X4 RECEPTOR MODULATORS AND RELATED PRODUCTS AND METHODS | 2020 |
|
RU2815715C2 |
| SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND USE THEREOF AS INHIBITORS OF UBIQUITIN-SPECIFIC PROCESSING PROTEASE 1 (USP1) | 2019 |
|
RU2833222C2 |
